Melanoma Institute Australia launches free e-learning education portal
20 June 2018
Melanoma Institute Australia (MIA) has launched a free e-learning portal to educate healthcare professionals about the latest advances in melanoma diagnosis and treatment to ensure best practice and equity of care for melanoma patients around the country.
The new online education portal is designed for healthcare professionals including specialists, dermatologists, GPs and nurses. It provides accredited videos and comprehensive training modules relating to the rapidly changing melanoma diagnostic and treatment landscape.
Melanoma Institute Australia Conjoint Medical Director, Professor Georgina Long, said the e-learning portal would ultimately improve melanoma patient care and outcomes within Australia and internationally.
“Our new education portal will be practice changing for healthcare professionals, particularly those who do not normally specialise in diagnosing and treating melanoma,” Professor Long said. “It gives them access to training modules covering best practice in diagnosing and managing melanoma, as well as translating world-leading research into clinical knowledge to ultimately improve patient outcomes.”
MIA Conjoint Medical Director, Professor Richard Scolyer, added, “We’re excited to bring together the collective expertise from MIA, which is the world’s largest research and treatment institute with a single focus on melanoma. The portal will ensure healthcare professionals have free 24/7 access to the latest advances in melanoma clinical practice and research, regardless of where they are located. This will benefit melanoma patients all over the world, and ultimately, save lives.” he said.
New content will be added to the site regularly and registered healthcare professionals can earn accreditation points. Healthcare professionals are invited to access the free site by registering at melanomaeducation.org.au
Melanoma March 2016 has officially begun with more than 300 people marching in Rockingham and Devonport.
MIA's new CEO Carole Renouf has been in her role only a month, but is already making plans for the future of MIA.
In the wake of Susie Maroney's recent announcement that she is battling melanoma, CEO Carole Renouf's opinion piece weighs in on the critical need we have in Australia to raise awareness about melanoma.
MIA's Georgina Long has been appointed Professor and awarded a coverted prize in medial research.
Melanoma March 2016 funding will be used to initiate an ambitious new project that will support the best possible care for melanoma patients around Australia through a new data and communication platform.
New research shows long-term survival in group of advanced melanoma patients treated with BRAF inhibitors
New MIA-led research has been published in the Journal of Clinical Oncology.
Melanoma March was officially launched today with the announcement of the national research project funded by the march.
Clinical research undertaken at MIA has been pivotal in supporting the recent Therapeutic Goods Administration approval of Opdivo (nivolumab) for advanced melanoma.
Maddison, the face of our Melanoma March campaign, knows the far-reaching effects that melanoma can have.
MIA's Dermatologist Associate Professor Pascale Guitera answers your most commonly-asked questions about sunscreen.
Statistics released by the Queensland Cancer Registry have revealed that melanoma is the most common cancer in young Queenslanders aged under 35, with rates in young women more than 20 per cent higher than in men.
As 2015 draws to a close, we took the opportunity to speak with Associate Professor Georgina Long to discuss her crucial role at Melanoma Institute Australia, and the current research projects she is working on.
MIA’s annual summer awareness campaign, which launched today (1 December), is reminding Australians how to protect themselves from the sun while highlighting the importance of encouraging friends, partners and family to do the same.
Your Guide to Early Melanoma is a new patient information pack to offer additional information for those affected by melanoma.
Special Event to share advances in diagnosis and treatment of both early and late stage melanoma
MIA researchers contribute to the discovery of ‘treasure trove’ of information leading to more targeted treatments for melanoma
Melanoma Institute Australia (MIA) patient Tara Moran and her seven year old daughter Olivia, who is fundraising for MIA, have been in the national media spotlight this week.
Melanoma Institute Australia’s (MIA’s) researchers have again been recognised, this time in the prestigious line-up for the 2015 Thomson Reuters Australian Citation & Innovation Awards.
New Federal Government funding means patients with the most deadly form of melanoma, will soon be able to receive treatment with the drug Keytruda® (pembrolizumab), on the Pharmaceutical Benefits Scheme (PBS).
The best ever results seen in metastatic melanoma treatment have been presented at the International ASCO Conference.